Pharma Exports Hit: ₹2,500–₹5,000 Cr Loss Looms on Freight Crisis

Indian pharmaceutical exporters face a potential financial catastrophe as supply chain congestion and soaring freight charges converge to disrupt shipments to the Middle East. The industry is bracing for losses ranging from ₹2,500 to ₹5,000 crore (approximately $300–$600 million USD) concentrated in March, a critical export month for the sector. This disruption reflects systemic vulnerabilities in global logistics networks, particularly the cold-chain infrastructure required for temperature-sensitive pharma products.

The escalating freight costs are driven by multiple factors: container shortages, port congestion, limited cold-chain container availability, and seasonal demand surges. For pharma exporters operating on thin margins with time-sensitive deliveries, these cost spikes are unsustainable. March shipments are especially critical for Middle Eastern distribution networks preparing for the summer months, making this timing particularly damaging.

This crisis underscores the structural fragility of India's pharma supply chain to emerging markets. Companies must urgently reassess freight hedging strategies, explore alternative routes and consolidation methods, and build buffer inventory if feasible. The broader implication is that emerging-market supply chains remain vulnerable to external shocks, and diversification of logistics partnerships is no longer optional—it is a competitive necessity.